ACP
Acuta Capital Partners Portfolio holdings
AUM
$147M
1-Year Est. Return
491.59%
This Fund
S&P 500
1 Year Est. Return
+491.59%
AUM
$147M
AUM Growth
+$50.5M
(+52%)
Holding
35
Top Buys
| 1 | +$6.2M | |
| 2 | +$3.1M | |
| 3 | +$2.63M | |
| 4 |
Tango Therapeutics
TNGX
|
+$2.44M |
| 5 |
Design Therapeutics
DSGN
|
+$1.18M |
Top Sells
| 1 | +$12.8M | |
| 2 | +$8.47M | |
| 3 | +$2.32M | |
| 4 |
Ascendis Pharma
ASND
|
+$1.95M |
| 5 |
Krystal Biotech
KRYS
|
+$1.87M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Revolution Medicines
RVMD
$19.7B
| $670K | 0.45% |
8,411
|
|
||
|
LBRX
27
LB Pharmaceuticals
LBRX
$607M
| $668K | 0.45% |
30,000
|
|
||
28
Pasithea Therapeutics
KTTA
$20.4M
| $581K | 0.39% |
+450,000
|
|
||
29
Unicycive Therapeutics
UNCY
$149M
| $346K | 0.24% |
59,985
|
|
||
|
NUVB.WS
30
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
| $30K | 0.02% |
90,832
|
|
||
31
Fulcrum Therapeutics
FULC
$558M
| – | – |
-57,141
|
|
||
|
32
Krystal Biotech
KRYS
$8.06B
| – | – |
-10,573
|
|
||
|
TRML
33
DELISTED
Tourmaline Bio
TRML
| – | – |
-268,451
|
|
||
|
34
Ascendis Pharma
ASND
$14.3B
| – | – |
-9,792
|
|
||
35
Cogent Biosciences
COGT
$6.31B
| – | – |
-102,907
|
|